Reduction of regulatory T cells by mogamulizumab, a defucosylated Anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and sézary syndrome

Clinical Cancer Research

Volumn 21, Issue 2, 2015, Pages 274-285

  Ni, Xiao ^a   Jorgensen, Jeffrey L ^b   Goswami, Meghali ^a   Challagundla, Pramoda ^b   Decker, William K ^b   Kim, Youn H ^c   Duvic, Madeleine A ^a  

^a University of Texas Health Science Center at Houston   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR4; MOGAMULIZUMAB; ANTINEOPLASTIC AGENT; CCR4 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CYTOTOXICITY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NATURAL KILLER CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SEZARY SYNDROME; TREATMENT OUTCOME; VERY ELDERLY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; K562 CELL LINE; METABOLISM; PATHOLOGY; SKIN NEOPLASMS; TRANSLATIONAL RESEARCH; TUMOR EMBOLISM;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; K562 CELLS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEOPLASTIC CELLS, CIRCULATING; RECEPTORS, CCR4; SEZARY SYNDROME; SKIN NEOPLASMS; T-LYMPHOCYTES, REGULATORY; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME;

EID: 84920973518     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0830     Document Type: Article

References (47)

1. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification ofmycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713-22.
2. Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, et al. Long-term outcomes of 1, 263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res 2012;18:5051-60.
3. Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T-cell lymphoma: An analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma. Int J Dermatol 2009;48:243-52.
4. Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wang J, et al. Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol 1999;11:81-8.
5. Wu XS, Lonsdorf AS, Hwang ST. Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. J Invest Dermatol 2009;129: 1115-9.
6. Ferenczi K, Fuhlbrigge RC, Pinkus JL, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 2002;119:1405-10.
7. Yano H, Ishida T, Inagaki A, Ishii T, Ding J, Kusumoto S, et al. Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: A novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. Clin Cancer Res 2007;13:6494-500.
8. Ishii T. [Development of an anti-CCR4 antibody, mogamulizumab, the first approved antibody made by POTELLIGENT((R)) technology]. Nihon Yakurigaku Zasshi 2013;142:167-71.
9. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4()CD25() regulatory T cells. J Exp Med 2001;194:847-53.
10. Sakaguchi S. Naturally arising CD4 regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62.
11. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
12. Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006;66: 5716-22.
13. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J Cancer 2010;127:759-67.
14. Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N, et al. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood 2005;105:1640-7.
15. Shiue LH, Ni X, Prieto VG, Jorgensen JL, Curry JL, Goswami M, et al. A case of invisible leukemic cutaneous T cell lymphoma with a regulatory T cell clone. Int J Dermatol 2013;52:1111-4.
16. Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 2001;115:885-92.
17. Heid JB, Schmidt A, Oberle N, Goerdt S, Krammer PH, Suri-Payer E, et al. FOXP3()CD25(-) tumor cells with regulatory function in sezary syndrome. J Invest Dermatol 2009;129:2875-85.
18. Banham AH. Cell-surface IL-7 receptor expression facilitates the purification of FOXP3() regulatory T cells. Trends Immunol 2006;27: 541-4.
19. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, et al. Phase I study of KW-0761, a defucosylated humanized anti- CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010;28: 1591-8.
20. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. J Clin Oncol 2012;30:837-42.
21. Duvic M, Pinter-Brown L, Foss FM, Sokol L, Jorgensen J, Spitalny GL, et al. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Blood (ASH Annual Meeting Abstract) 2010;116:962.
22. Kim YH, Pinter-Brown L, Foss F, Sokol L, Jorgensen JL, Spitalny GL, et al. CO26. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients. Melanoma Res 2011;21:e15-e6.
23. Duvic M, Pinter-Brown L, Foss F, Sokol L, Jorgensen J, Ni X, et al. Correlation of target molecule expression and overall response in refractory cutaneous T-cell lymphoma patients dosed with mogamulizumab (KW- 0761), a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4). Blood 2012;120:3697.
24. Ni X, Jorgensen JL, GoswamiM, Challagundla P, Decker WK, Kim YH, et al. Effects of anti-CCR4 antibody (KW-0761) on regulatory T cells and natural killer cells in patients with cutaneous T-cell lymphoma. Blood 2011; 118:204-5.
25. Ni X, Richmond HM, Liao XM, Decker WK, Shiue LH, Shpall EJ, et al. Induction of T-cell responses against cutaneous T-cell lymphomas ex vivo by autologous dendritic cells transfected with amplified tumor mRNA. J Invest Dermatol 2008;128:2631-9.
26. Goswami M, Duvic M, Dougherty A, Ni X. Increased Twist expression in advanced stage of mycosis fungoides and Sezary syndrome. J Cutan Pathol 2012;39:500-7.
27. Han T, Abdel-Motal UM, Chang DK, Sui J, Muvaffak A, Campbell J, et al. Human anti-CCR4 minibody gene transfer for the treatment of cutaneous T-cell lymphoma. PLoS ONE 2012;7:4.
28. Chang DK, Sui J, Geng S, Muvaffak A, Bai M, Fuhlbrigge RC, et al. Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther 2012;11:2451-61.
29. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014;32:1157-63.
30. Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T, et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS ONE 2012;7:25.
31. Frankel AE, Zuckero SL, Mankin AA, Grable M, Mitchell K, Lee YJ, et al. Anti- CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphoma. Curr Drug Targets 2009;10:104-9.
32. Papalas JA, Sebastian S, Wang E. Molecular evidence of a genotypically novel large T-cell lymphoma after anti-CD4 therapy for refractory mycosis fungoides. Leuk Lymphoma 2011;52:905-7.
33. Abi-Younes S, Si-Tahar M, Luster AD. The CC chemokines MDC and TARC induce platelet activation via CCR4. Thromb Res 2001;101:279-89.
34. Clemetson KJ, Clemetson JM, Proudfoot AE, Power CA, Baggiolini M, Wells TN. Functional expression of CCR1, CCR3, CCR4, and CXCR4 chemokine receptors on human platelets. Blood 2000;96:4046-54.
35. Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3CD4 regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 2013;14:14.
36. Sokolowska-Wojdylo M, Wenzel J, Gaffal E, Lenz J, Speuser P, Erdmann S, et al. Circulating clonal CLA() and CD4() T cells in Sezary syndrome express the skin-homing chemokine receptors CCR4 and CCR10 as well as the lymph node-homing chemokine receptor CCR7. Br J Dermatol 2005;152:258-64.
37. Jones D, O'Hara C, Kraus MD, Perez-Atayde AR, Shahsafaei A, Wu L, et al. Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. Blood 2000;96:685-90.
38. Olkhanud PB, Baatar D, Bodogai M, Hakim F, Gress R, Anderson RL, et al. Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. Cancer Res 2009;69:5996-6004.
39. Jakubzick C, Wen H, Matsukawa A, Keller M, Kunkel SL, Hogaboam CM. Role of CCR4 ligands, CCL17 and CCL22, during Schistosoma mansoni egg-induced pulmonary granuloma formation in mice. Am J Pathol 2004;165:1211-21.
40. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3 regulatory T cells in the human immune system. Nat Rev Immunol 2010;10:490-500.
41. Miyara M, Sakaguchi S. Human FoxP3()CD4() regulatory T cells: Their knowns and unknowns. Immunol Cell Biol 2011;89:346-51.
42. Golovina TN, Vonderheide RH. Regulatory T cells: overcoming suppression of T-cell immunity. Cancer Journal 2010;16:342-7.
43. Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, et al. In situ vaccination against mycosis fungoides by intra tumoral injection of a TLR9 agonist combined with radiation: A phase 1/2 study. Blood 2012;119:355-63.
44. Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, et al. A CCR4 antagonist combined with vaccines induces antigen-specific CD8 T cells and tumor immunity against self antigens. Blood 2011;118: 4853-62.
45. Houot R, Kohrt H, Levy R. Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. Oncoimmunology 2012;1:957-8.
46. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, et al. CD137 stimulation enhances the anti lymphoma activity of anti-CD20 antibodies. Blood 2011;117:2423-32.
47. Kohrt HE, Houot R, Weiskopf K, Goldstein MJ, Scheeren F, Czerwinski D, et al. Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012;122:1066-75.